All In Biotech

Drug Trial Radar · NCT05418868

A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

A Phase I, Multi-centre, Open-label, Single Dose Escalation Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Long-acting Cabotegravir Co-administered With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

214

Planned (sponsor's estimate)

Start

Jun 14, 2022

Primary completion

Mar 31, 2028

Study completion Mar 31, 2028

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
Collaborators
GlaxoSmithKline; Janssen Sciences Ireland Unlimited Company
First posted
Jun 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label, dose-escalation study to investigate the safety, tolerability and pharmacokinetics (PK) of single subcutaneous (SC) administration of long acting (LA) Cabotegravir (CAB) 200 milligrams per milliliter (mg/mL) with Recombinant Human Hyaluronidase PH20 (rHuPH20) (Part A), a single-dose or repeat-dose SC or intramuscular (IM) administration of LA CAB (greater than or equal to) \>=400 mg/mL (Part C), single-dose IM administration of LA CAB Formulation I (Part C Cohort C8) and LA CAB Formulation J (Part C Cohort C11), and a single-dose or repeat-dose IM administration of rilpivirine (RPV) (Part E). Part A of the study (CAB 200 mg/mL with rHuPh20) has been closed to further enrolment based on preliminary results. Part D of the study (CAB \>=400 mg/mL with rHuPH20) will not be conducted due to changes in the study design.

Conditions

  • HIV Infections

Interventions

  • Cabotegravir 200 mg/mLDrug

    CAB 200 mg/mL will be administered.

  • CAB >=400 mg/mLDrug

    CAB \>=400 mg/mL will be administered by IM or SC injection.

  • CAB Formulation IDrug

    CAB Formulation I will be administered by IM injection.

  • CAB Formulation JDrug

    CAB Formulation J will be administered by IM injection.

  • rHuPH20Drug

    rHuPH20 will be administered.

  • RPVDrug

    RPV will be administered by IM injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed plasma concentration (Cmax) of CAB and RPVTime frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  2. Time of maximum observed plasma concentration (tmax) of CAB and RPVTime frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  3. Area under the concentration - time curve from time zero to infinity (AUC[0-inf]) of CAB and RPVTime frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  4. Area under the concentration - time curve from time zero to time of last quantifiable concentration or 4 weeks following the injection whichever is earlier (AUC[0-t]) of CAB and RPVTime frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Cohorts Part A, C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  5. Area under the concentration - time curve from time zero to last quantifiable time point or 8 weeks following the injection whichever is earlier [AUC(0-t)]Time frame: Up to end of study (Week 72 for Cohort C10 and C12 [Part C])
  6. Plasma Concentration of CAB and RPV at Week 4Time frame: Week 4
  7. Plasma Concentration of CAB and RPV at Week 8Time frame: Week 8
  8. Plasma Concentration of CAB and RPV at Week 12Time frame: Week 12
  9. Plasma Concentration of CAB and RPV at Week 16Time frame: Week 16
  10. Plasma Concentration of CAB and RPV at Week 24Time frame: Week 24
  11. Plasma Concentration of RPV at Week 32Time frame: Week 32
  12. Plasma Concentration of CAB at Week 36Time frame: Week 36
  13. Plasma Concentration of RPV at Week 40Time frame: Week 40
  14. Plasma Concentration of CAB and RPV at Week 48Time frame: Week 48
  15. Plasma Concentration of CABTime frame: At weeks 56, 64 and 72 for Cohorts C10, C11 and C12 [Part C]
  16. Plasma Concentration of RPV at Week 56Time frame: Week 56
  17. Plasma Concentration of RPV at Week 64Time frame: Week 64
  18. Plasma Concentration of RPV at Week 72Time frame: Week 72
  19. Apparent terminal phase half-life (t1/2) of CAB and RPVTime frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  20. Apparent long-acting absorption rate constant (KA-LA) of CAB and RPVTime frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  21. Number of Participants with Non-serious Adverse Events (non-SAEs) and Serious Adverse Events (SAEs)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  22. Number of Participants with AEs by SeverityTime frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  23. Absolute value of hematology parameter: Platelet count (cells per microliter)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  24. Absolute values of hematology parameters: Reticulocytes (Percentage of reticulocytes)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  25. Absolute values of hematology parameters: Hematocrit (Proportion of red blood cells in blood)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  26. Absolute values of hematology parameters: Hemoglobin (Hgb) (grams per deciliter)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C] , and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  27. Absolute value of hematology parameter: Red Blood Cell Count (RBC) (million cells per microliter)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  28. Absolute value of hematology parameter: Mean Corpuscle Volume (MCV) (Femtoliters)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  29. Absolute value of hematology parameter: Mean Corpuscle Hemoglobin (MCH) (Picograms)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  30. Absolute values of hematology parameters: Differential count of Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per liter)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  31. Absolute values of Clinical Chemistry parameters: Glucose (fasting), Blood Urea Nitrogen (BUN), Creatinine, Sodium, Potassium, Calcium, Direct Bilirubin and Total Bilirubin (milligrams per deciliter)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  32. Absolute values of Clinical Chemistry parameters: AST/SGOT, ALT/ SGPT, ALP and CPK (International Units per liter)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  33. Absolute values of Clinical chemistry parameters: Albumin and Total Protein (Grams per deciliter)Time frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  34. Change from Baseline in hematology parameter: Platelet count (cells per microliter)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  35. Change from Baseline in hematology parameters: Reticulocytes (Percentage of reticulocytes)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Cohorts Part A, C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  36. Change from Baseline in hematology parameters: Hematocrit (Proportion of red blood cells in blood)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  37. Change from Baseline in hematology parameters: Hgb (grams per deciliter)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  38. Change from Baseline in hematology parameter: RBC Count (million cells per microliter)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  39. Change from Baseline in hematology parameter: MCV (Femtoliters)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  40. Change from Baseline in hematology parameter: MCH (picograms)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  41. Change from Baseline in hematology parameters: Differential count of Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (Giga cells per liter)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  42. Change from Baseline in Clinical Chemistry parameters: Glucose (fasting), BUN, Creatinine, Sodium, Potassium, Calcium, Direct Bilirubin and Total Bilirubin (milligrams per deciliter)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  43. Change from Baseline in Clinical Chemistry parameters: AST/SGOT, ALT/ SGPT, ALP and CPK (International Units per liter)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  44. Change from Baseline in Clinical chemistry parameters: Albumin and Total Protein (Grams per deciliter)Time frame: Baseline (Day 1) and up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])
  45. Number of participants with maximum toxicity grades increase from Baseline in hematology and clinical chemistryTime frame: Up to end of study (Week 78 for Cohorts C1 and C3 [Part C], Week 52 for Part A, Cohorts C2, C4, C5, C6, C7, C8, C9 [Part C], and Week 72 for Part E and Cohorts C10, C11 and C12 [Part C])

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Orlando, Florida · Completed

  • GSK Investigational Site

    Las Vegas, Nevada · Recruiting

  • GSK Investigational Site

    Austin, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.